Management of postmenopausal osteoporosis: Position statement of the North American Menopause Society

Menopause

Volumn 9, Issue 2, 2002, Pages 84-101

  Gallagher, J Christopher ^a   Ettinger, Bruce ^a   Gass, Margery L S ^a   Kagan, Risa ^a   McClung, Betsy L ^a   McClung, Michael R ^a   Simon, James A ^a  

^a NAMS   (United States)

Author keywords

Bisphosphonates; Bone mineral density; Calcitonin; Calcium; Estrogen replacement therapy; Fractures; Menopause; Osteoporosis; Parathyroid hormone; Selective estrogen receptor modulators; Vitamin D

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCITRIOL; CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; PHOSPHONIC ACID DERIVATIVE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THIAZIDE DIURETIC AGENT; TIBOLONE; VITAMIN D;

ALCOHOL CONSUMPTION; ARTICLE; BONE ATROPHY; BONE MINERAL; BONE STRENGTH; CLINICAL TRIAL; DIET THERAPY; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GENETICS; HIP FRACTURE; HOT FLUSH; HUMAN; INFLAMMATION; LIFESTYLE; MEDLINE; MORBIDITY; MORTALITY; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RISK FACTOR; SMOKING CESSATION; SPINE FRACTURE; VEIN THROMBOSIS; VITAMIN SUPPLEMENTATION;

CALCITONIN; CALCIUM, DIETARY; DIET; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; EXERCISE; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SMOKING CESSATION; VITAMIN D;

EID: 0036190678     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (129)

1. Users' guides to the medical literature. IX. A method for grading health care recommendations
2. Guidelines for clinical guidelines
3. The North American Menopause Society develops consensus opinions
4. Osteoporosis prevention, diagnosis, and therapy
5. Prevalence of low femoral bone density in older US adults from NHANES III
6. How many women have osteoporosis?
7. Fractures attributable to osteoporosis: Report from the National Osteoporosis Foundation
8. Updated data on proximal femur bone mineral levels of US adults
9. A model of lifetime osteoporosis impact
10. Risk of new vertebral fracture in the year following a fracture
11. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis
12. Increased risk of tooth loss is related to bone loss at the whole body, hip, and spine
13. Bone mineral density and depression: A community study in women
14. Optimal calcium intake
15. Characterization of perimenopausal bone loss: A prospective study
16. Genetic determinants of bone mass in adult women: A reevaluation of the twin model and the potential importance of gene interaction on heritability estimates
17. Genetic determinants of bone mass in adults: A twin study
18. Factors associated with appendicular bone mass in older women
19. Reduced bone mass in daughters of women with osteoporosis
20. Bone mass is low in relatives of osteoporotic patients
21. Teenage and current calcium intake are related to bone mineral density of the hip and forearm in women aged 30-39 years
22. Nutrition, osteoporosis, and aging
23. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: Effect of age and dietary calcium
24. The role of calcium in peri- and postmenopausal women: Consensus opinion of the North American Menopause Society
25. Increase in femoral bone density in young women following high-impact exercise
26. High-impact exercise promotes bone gain in well-trained female athletes
27. Hip bone mineral density is improved by high-impact aerobic exercise in postmenopausal women and men over 50 years
28. The temporal response of bone to unloading
29. Forearm bone loss in hemiplegia: A model for the study of immobilization osteoporosis
30. Can vigorous exercise play a role in osteoporosis prevention? A review
31. Cigarette smoking, obesity, and bone mass
32. Smoking and bone loss among postmenopausal women
33. Prospective study of factors influencing the onset of natural menopause
34. Cigarette smoking, alcohol consumption, and risk for hip fracture in women
35. Smoking and bone metabolism in elderly women
36. Cigarette smoking, serum estrogens and bone loss during hormone replacement therapy early after menopause
37. Alcohol intake and bone mineral density in elderly men and women: The Framingham study
38. Alcohol intake and bone metabolism in elderly women
39. Vertebral fracture epidemiology
40. Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures
41. Forearm fracture
42. Current methods and recent advances in the diagnosis of osteoporosis
43. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis
44. An update on the diagnosis and assessment of osteoporosis with densitometry
45. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis
46. Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean
47. Ten-year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds
48. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
49. Practical clinical applications of biochemical markers of bone turnover: Consensus of an expert panel
50. Effect of dietary protein on bone loss in elderly men and women: The Framingham Osteoporosis study
51. Benefits of oral protein supplementation in elderly patients with fracture of the proximal femur
52. Calcium potentiates the effect of estrogen and calcitonin on bone mass: Review and analysis
53. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, phase 1, 1988-91
54. Prevalence of vitamin D insufficiency in an adult normal population
55. Calciotropic hormones and bone markers in the elderly
56. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women
57. Vitamin D3 and calcium to prevent hip fractures in elderly women
58. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older
59. Effect of magnesium on the intestinal absorption of calcium in man
60. The importance of magnesium in the management of primary postmenopausal osteoporosis
61. Trabecular bone density in a two-year controlled trial of peroral magnesium in osteoporosis
62. Magnesium status and ageing: An update
63. Magnesium deficiency: Possible role in osteoporosis associated with gluten-sensitive enteropathy
64. The role of isoflavones in menopausal health: Consensus opinion of The North American Menopause Society
65. Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial. Ipriflavone Multicenter European Fracture study
66. The effects of exercise on falls in elderly patients. A preplanned meta-analysis of the FICSIT trials. Frailty and Injuries: Cooperative Studies of Intervention Techniques
67. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures: A randomized controlled trial
68. Relative influence of physical activity, muscle mass and strength on bone density
69. Estrogen therapy and variable-resistance weight training increase bone mineral in surgically menopausal women
70. Alcohol consumption and hip fractures: The Framingham study
71. Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly
72. A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: Consensus opinion of The North American Menopause Society
73. Treatment of osteoporosis
74. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study): A randomized controlled trial
75. Effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen
76. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
77. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: A randomized, controlled trial
78. Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels
79. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss
80. Estrogen treatment of patients with established postmenopausal osteoporosis
81. Timing of postmenopausal estrogen for optimal bone mineral density: The Rancho Bernardo study
82. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss
83. The effect of postmenopausal estrogen therapy on bone density in elderly women
84. Estrogen therapy arrests bone loss in elderly women
85. Hormone therapy to prevent disease and prolong life in postmenopausal women
86. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials
87. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group
88. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS)
89. Hormone replacement therapy and risk of hip fracture: Population based, case-control study
90. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
91. Estrogen replacement therapy and breast cancer survival in a large screening study
92. Alendronate prevents postmenopausal bone loss in women without osteoporosis: A double-blind, randomized, controlled trial
93. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the Early Postmenopausal Intervention Cohort Study. A randomized, controlled trial
94. Skeletal benefits of alendronate: 7-Year treatment of postmenopausal osteoporotic women
95. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial
96. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
97. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
98. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
99. Effect of risedronate on the risk of hip fracture in elderly women
100. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis
101. Use of bisphosphonates in the treatment of osteoporosis: Prevention and management of osteoporosis: Consensus statements from the scientific advisory board of the Osteoporosis Society of Canada
102. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial
103. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
104. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
105. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial
106. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation
107. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose response study
108. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study
109. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures
110. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study
111. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
112. 1-34 on fractures and bone mineral density in postmenopausal women with osteoporosis
113. Tibolone and the prevention of bone loss
114. Prevention of postmenopausal bone loss using tibolone or conventional peroroal or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone
115. Prevention of bone loss with tibolone in postmenopausal women: Results of two randomized, double-blind, placebo-controlled, dose-finding studies
116. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
117. HMG-CoA reductase inhibitors and the risk of hip fractures in the elderly
118. HMG-CoA reductase inhibitors and the risk of fractures
119. Use of statins and risk of fractures
120. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: A randomized, double-blind, placebo-controlled trial
121. Alendronate and estrogen effect in postmenopausal women with low bone mineral density
122. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
123. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women
124. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis